Beth Phuong Nguyen

US Patent:

7384910, Jun 10, 2008

Filed:

Dec 16, 2004

Appl. No.:

11/016706

Inventors:

Gerardo M. Castillo - Bothell WA, US
Thomas P. Lake - Snohomish WA, US
Beth P. Nguyen - Gurnee IL, US
Virginia J. Sanders - San Francisco CA, US
Alan D. Snow - Lynnwood WA, US

International Classification:

A61K 38/08

US Classification:

514 2

Abstract:

A pharmaceutical composition comprising peptide Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D-amino acid.

US Patent:

7601876, Oct 13, 2009

Filed:

Mar 5, 2007

Appl. No.:

11/714894

Inventors:

Alan D. Snow - Lynnwood WA, US
Beth P. Nguyen - Gurnee IL, US
Gerardo M. Castillo - Bothell WA, US
Virginia J. Sanders - San Francisco CA, US
Thomas P. Lake - Snohomish WA, US
Lesley Larsen - Port Chalmers, NZ
Rex T. Weavers - Dunedin, NZ
Stephen D. Lorimer - Dunedin, NZ
David S. Larsen - Port Chalmers, NZ
David L. Coffen - Belcamp MD, US
Charlotte Coffen, legal representative - Belcamp MD, US

Assignee:

Proteotech, Inc. - Kirkland WA

International Classification:

C07C 33/00
C07C 49/00
C07C 209/00
C07C 211/00
C07C 233/00
C07C 239/00
C07C 275/00
A61K 31/00

US Classification:

568331, 568807, 568809, 564 52, 564158, 564170, 564175, 564179, 564367, 564384, 514598, 514616, 514622, 514649, 514650, 514655, 514685, 514734

Abstract:

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

US Patent:

7759311, Jul 20, 2010

Filed:

Apr 2, 2007

Appl. No.:

11/732226

Inventors:

Gerardo Castillo - Bothell WA, US
Thomas Lake - Snohomish WA, US
Beth Nguyen - Gurnee IL, US
Virginia Sanders - San Francisco CA, US
Alan D. Snow - Lynnwood WA, US

Assignee:

Proteotech, Inc. - Kirkland WA

International Classification:

A61K 38/08

US Classification:

514 16

Abstract:

A pharmaceutical composition comprising a peptide consisting of Arg-Val-Ala-Val-Ile-Met-Gly-amide-having at least one D-amino acid.

US Patent:

8003612, Aug 23, 2011

Filed:

Nov 26, 2008

Appl. No.:

12/323944

Inventors:

Thomas Lake - Snohomish WA, US
Alan D. Snow - Lynnwood WA, US
Gerardo Castillo - Bothell WA, US
Beth Nguyen - Gurnee IL, US
Virginia Sanders - San Francisco CA, US
Qubai Hu - Kirkland WA, US
Judy A. Cam - Bellevue WA, US

Assignee:

Proteotech Inc. - Kirkland WA

International Classification:

A61K 38/08

US Classification:

514 178, 514 217

Abstract:

Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease.

US Patent:

8163957, Apr 24, 2012

Filed:

Jul 16, 2010

Appl. No.:

12/837721

Inventors:

Alan D Snow - Lynnwood WA, US
Beth Nguyen - Trophy Club TX, US
Gerardo Castillo - Bothell WA, US
Virginia Sanders - San Francisco CA, US
Thomas Lake - Snohomish WA, US
Lesley Larsen - Dunedin, NZ
Rex T Weavers - Dunedin, NZ
Stephen Lorimer - Dunedin, NZ
David Larsen - Dunedin, NZ
David L Coffen - San Diego CA, US
Charlotte Coffen, legal representative - Belcamp MD, US

Assignee:

ProteoTech, Inc. - Kirkland WA

International Classification:

C07C 237/14
C07C 237/20
A61K 31/16

US Classification:

564155, 514616

Abstract:

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

US Patent:

8586585, Nov 19, 2013

Filed:

Mar 6, 2012

Appl. No.:

13/413417

Inventors:

Alan D. Snow - Lynnwood WA, US
Beth Nguyen - Trophy Club TX, US
Gerardo Castillo - Bothell WA, US
Virginia Sanders - San Francisco CA, US
Thomas Lake - Snohomish WA, US
Lesley Larsen - Dunedin, NZ
Rex T. Weavers - Dunedin, NZ
Stephen Lorimer - Dunedin, NZ
David Larsen - Dunedin, NZ
Charlotte Coffen - Belcamp MD, US

Assignee:

ProteoTech, Inc. - Kirkland WA

International Classification:

A01N 43/58
A61K 31/50
A61K 31/497
A01N 43/40
A61K 31/435

US Classification:

514247, 51425212, 514277

Abstract:

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

US Patent:

20080044917, Feb 21, 2008

Filed:

Jul 14, 2006

Appl. No.:

11/487149

Inventors:

Beth Nguyen - Gurnee IL, US
Paula Choi - Solana Beach CA, US
Virginia Sanders - San Francisco CA, US
Gerardo Castillo - Bothell WA, US
Alan Snow - Lynnwood WA, US

International Classification:

G01N 33/00

US Classification:

436094000

Abstract:

A method of induction of amyloid plaques includes immobilizing a quantity of a selected sulfated glycosaminoglycan (SGAG) on a selected medium and adding to the immobilized SGAG on the medium a quantity of dissolved low fibrillar Aβ 1-40 (LFAβ). The LFAβ is added preferably in a Aβ:SGAG w/w ratio of about 1:1. SGAGs are preferably selected from heparin, heparan sulfate, keratan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate. Screening methods and kits for screening either immobilize a quantity of a selected sulfated glycosaminoglycan (SGAG) on a selected medium, followed by adding to a quantity of dissolved low fibrillar Aβ 1-40 (LFAβ) a selected quantity of the selected amyloid therapeutic candidate to create a test solution, and then adding to the immobilized SGAG on the medium a selected quantity of the test solution to test for inhibition, or preform amyloid plaques on the medium by immobilizing a quantity of a selected sulfated glycosaminoglycan (SGAG) or a GAG-related macromolecule on a selected medium and then adding a selected quantity of dissolved low fibrillar Aβ 1-40 (LFAβ), followed by adding to the amyloid plaques on the medium a selected quantity of a test solution of a selected amyloid therapeutic candidate to test for disruption.

US Patent:

20080306142, Dec 11, 2008

Filed:

May 12, 2008

Appl. No.:

12/119212

Inventors:

Gerardo Castillo - Bothell WA, US
Beth Nguyen - Gurnee IL, US
Paula Choi - Seattle WA, US
Lesley Larsen - Dunedin, NZ
Stephen Lorimer - Dunedin, NZ
Alan Snow - Lynnwood WA, US

International Classification:

A61K 31/353
A61P 25/28

US Classification:

514456

Abstract:

Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus . The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.